Accession |
PRJCA013557 |
Title |
SHR-1802-101-Tolerability, safety and pharmacokinetic characteristics of anti-LAG3 antibody SHR-1802 in patients with advanced malignant tumors |
Relevance |
Medical |
Data types |
Clinical, imaging, metabolic, biomarker data, etc
|
Organisms |
Homo sapiens
|
Description |
SHR-1802-101-Tolerability, safety and pharmacokinetic characteristics of anti-LAG3 antibody SHR-1802 in patients with advanced malignant tumors |
Sample scope |
Multiisolate |
Release date |
2022-11-29 |
Grants |
Agency |
program |
Grant ID |
Grant title |
NA
|
NA
|
NA
|
NA
|
|
Submitter |
weiqing ge
weiqing
ge (weiqing.ge@hengrui.com)
|
Organization |
Jiangsu Hengrui pharmaceutical Co.LTD |
Submission date |
2022-11-29 |